Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors

Current Opinion in Hematology

Volumn 15, Issue 2, 2008, Pages 134-139

  Sahay, Tannu ^a   Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myeloid leukemia; Imatinib; Minimal residual disease; Real time RT PCR; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; FOLLOW UP; HUMAN; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE;

DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 40049109527     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282f42898     Document Type: Review

References (63)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-1340.
2. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-2653.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
4. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly-diagnosed chronic myeloid leukaemia. N Engl J Med 2003; 349:1423-1432.
5. Druker B, Guilhot F, O'Brien SG, et al., for the IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006; 355:2408-2417. This report presents long-term follow-up results of patients included in the original IRIS study, demonstrating sustained benefit from imatinib.
6. Schiffer CA. Bcr/abl tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357:258-265. This is a case-based overview of CML management.
7. Bocchia M, Forconi F, Lauria F. Emerging drugs in chronic myeloid leukemia. Exp Opin Emerg Drugs 2006; 11:651-664. This report outlines the newer TKIs on the horizon and their potential role.
8. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109:2303-2309. This report outlines the efficacy of dasatinib in imatinib failures.
9. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109:4143-4150. This is a recent article on experience with dasatinib.
10. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541. Initial experience with dasatinib in patients who are no longer responding to imatinib treatment is presented.
11. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-2551. This report summarizes initial experience with nilotinib in patients who are no longer responding to imatinib treatment
12. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37. This report provides a detailed review and recommendations regarding CML monitoring, including PCR standardization.
13. Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 2002; 107:64-75.
14. + cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 2007; 9 Aug [Epub ahead of print]. This paper emphasizes the presence of residual leukemia in patients with CCyR.
15. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-4707.
16. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107:4532-4539. Persistence of progenitor cells in CML is also demonstrable with dasatinib.
17. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29:94-97.
18. Cortes J, Talpaz M, O'Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 1998; 16:3279-3285.
19. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101:1941-1949.
20. Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004; 104:1979-1988.
21. Mühlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission asssessment. Genes Chromosomes Cancer 1998; 21:90-100.
22. Cuneo A, Bigoni R, Emmanuel B, et al. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 1998; 12:1718-1723.
23. Garcia-Isidoro M, Tabernero MD, Garcia JL, et al. Detection of the bcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: comparison with conventional cytogenetics and implications for minimal residual disease detection. Hum Pathol 1997; 28:154-159.
24. Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 1990; 250:559-562.
25. Yanagi M, Shinjo K, Takeshita A, et al. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 1999; 13:542-552.
26. Chase A, Grand F, Zhang JG, et al. Factors influencing the false positive and negative rates of BCRABL fluorescence in-situ hybridization. Genes Chromosomes Cancer 1997; 18:246-253.
27. Press RD, Love Z, Tronnes AA, Yang R, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006; 107:4250-4256. This study demonstrates the co-relation of the level of bcr-abl mRNA levels at the time of CCyR with duration of CCyR.
28. Wiedemann LM, Bartram CR. Polymerase chain reaction for detection of residual leukaemia. Lancet 1989; 1:928-929.
29. Hughes T, Goldman JM. Improved results with PCR for chronic myeloid leukaemia. Lancet 1990; 336:812.
30. Wang L, Pearson K, Pilleri L, et al. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118:771-777.
31. Hughes T, Martiat P, Morgan G, et al. Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet 1990; 335:50.
32. Lion T, Henn T, Gaiger A, et al. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341:275-276.
33. Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-a therapy by competitive polymerase chain reaction. Blood 1996; 87:1549-1555.
34. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8:186-189.
35. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104:2926-2932.
36. Malinge MC, Mahon FX, Delfau MH, et al. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 1992; 82:701-707.
37. Amabile M, Giannini B, Testoni N, et al. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 2001; 86:252-259.
38. Stentoft J, Pallisgaard N, Kjeldsen E, et al. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67:302-308.
39. Guo JQ, Lin H, Kantarjian H, et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002; 16:2447-2453.
40. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106:2520-2526.
41. White D, Saunders V, Grigg A, et al. Measurement of In vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25:4445-4451. The effect of degree of in vivo bcr-abl kinase inhibition on imatinib response. Data from the TIDEL and OCT trials.
42. Merx K, Müller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients. Leukemia 2002; 16:1579-1583.
43. Branford S, Moore S, Grigg A, et al. Early measurement of BCR-ABL mRNA blood levels may be predictive of subsequent achievement of major cytogenetic response to Glivec in chronic myeloid leukaemia [abstract]. Blood 2001; 98:613a.
44. Stock W, Westbrook CA, Peterson B, et al. Value of molecular monitoring during treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 1997; 15:26-36.
45. Jabbour E, Kantarjian H, Abruzzo L, et al. Chromosomal abnormalities In Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007; 110:2991-2995. This report outlines the significance of chromosomal abnormalities in Philadelphia-negative CML cells appearing during treatment with imatinib.
46. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61:1441-1446.
47. Wang L, Knight K, Lucas C, Clark RE. The role of BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukaemia. Haematologica 2006; 91:235-239. The authors explain the significance of the rising trend of bcr-abl transcripts and development of kinase domain mutations.
48. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2007; 23:4100-4109. This report discusses the significance of ABL mutation in late chronic phase CML.
49. Saldanha J, Silvy M, Beaufils N, et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia 2007; 21:1481-1487. Reference gene characterization for RT-PCR is presented.
50. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 2003; 17:2318-2357.
51. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukaemia. Recommendations from an expert panel on behalf of the European Leukemia-net. Blood 2006; 108:1809-1820. The authors make a proposal for defining response to imatinib.
52. Azam M, Daley GQ. Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006; 10:67-76.
53. McLean LA, Gathmann I, Capdeville R, et al. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004; 10:155-165.
54. + cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006; 20:1028-1034.
55. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908-916. See annotation to [58•;].
56. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233-1237. See annotation to [58•;].
57. Rosti G, Martinelli G, Baccarani M. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13:15. See annotation to [58•;].
58. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006-2013. This report and [55•;-57•] identify the possible long-term and/or potential serious side effects of imatinib therapy.
59. Colombat M, Fort MP, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006; 91:162-168.
60. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28 (Suppl 1):S71-S73.
61. Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 2004; 76:275-278.
62. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood 2007; 109:58-60. This is a case series on effect of imatinib discontinuation.
63. Carella AM, Lerma E. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol 2007; 86:749-752. This report explores the possibility of dose reduction of imatinib after MMR.